A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vanda Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01402076
First received: July 19, 2011
Last updated: February 14, 2014
Last verified: February 2014

July 19, 2011
February 14, 2014
August 2011
August 2011   (final data collection date for primary outcome measure)
  • CYP3A4 Pharmacokinetics [ Time Frame: Days 1 and 18 ] [ Designated as safety issue: Yes ]
    Composite of 24 hour pharmacokinetic parameters of midazolam will be compared between Day 1 and Day 18.
  • CYP2C8 Pharmacokinetics [ Time Frame: Days 3 and 20 ] [ Designated as safety issue: Yes ]
    Composite of 24 hour pharmacokinetic parameters of rosiglitazone will be compared between Day 3 and 20.
Same as current
Complete list of historical versions of study NCT01402076 on ClinicalTrials.gov Archive Site
  • Midazolam PK [ Time Frame: Days 1 and 17 ] [ Designated as safety issue: No ]
    Composite pharmacokinetic parameters of midazolam and α-hydroxymidazolam will be compared between Day 1 and Day 18.
  • Rosiglitazone PK [ Time Frame: Days 3 and 20 ] [ Designated as safety issue: No ]
    Composite of 24 hour pharmacokinetic parameters of rosiglitazone will be compared between Day 3 and Day 20.
  • Tasimelteon multiple dose pharmacokinetics [ Time Frame: Days 4-21 ] [ Designated as safety issue: No ]
    Composite of 24 hour pharmacokinetic parameters of tasimelteon and tasimelteon metabolites M9, M11, M12, M13, and M14, at Days 5, 8, 11, 14 (Group 1 only), and Days 17 and 19 (Groups 1 and 2).
  • Tasimelteon safety and tolerability [ Time Frame: Days 1-21 ] [ Designated as safety issue: Yes ]
    Safety of multiple oral doses of 20 mg of tasimelteon alone and in combination with 10 mg of midazolam as measured by vital signs, ECG, and adverse event reporting.
Same as current
Not Provided
Not Provided
 
A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects
An Open-Label, Single-Sequence Study to Assess the Effect of Multiple Doses of Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes Using Midazolam and Rosiglitazone as Substrates in Healthy Subjects

The purpose of this research study is to understand whether there is any difference in the amount of midazolam (including its breakdown product) in the blood when midazolam is given with tasimelteon, and whether there is any difference in the amount of rosiglitazone in the blood when rosiglitazone is given with tasimelteon.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Healthy Volunteers
  • Drug: Tasimelteon
    20mg daily dosing, Days 4-20
  • Drug: Rosiglitazone
    4mg, single dose, Days 3 and 20
    Other Name: Avandia
  • Drug: Midazolam
    10mg, single dose, Days 1 and 18
  • Experimental: Steady State PK Group
    Interventions:
    • Drug: Tasimelteon
    • Drug: Rosiglitazone
    • Drug: Midazolam
  • Experimental: No steady state PK
    Interventions:
    • Drug: Tasimelteon
    • Drug: Rosiglitazone
    • Drug: Midazolam
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
August 2011
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Ability and acceptance to provide written informed consent;
  2. Subjects must be males or females between 18 and 55 years of age, inclusive;
  3. Female subjects of childbearing potential must be non-pregnant and non-lactating and have a negative serum or urine pregnancy test at the Screening visit and at Check-in (Days -1) and agree not to attempt to become pregnant during the course of the study. Female subjects of childbearing potential (including peri-menopausal women who have had a menstrual bleeding within 1 year) must be using appropriate birth control (e.g. intrauterine device [IUD], diaphragm or condom with spermicidal jelly or foam or abstinence, or cervical cap) for a period of 35 days before the first dosing, for the duration of the study, and for one month after the last dose;

    a. Note: Women are not permitted to use hormonal methods of birth control (e.g. oral contraceptives, hormonal intrauterine device [IUD], patch and steroids) and must use another acceptable method of birth control during the study and for one month after the last dose. Women currently taking oral contraceptives will be required to discontinue their regimen two weeks prior to first dosing.

  4. Subjects with Body Mass Index (BMI) of >18 and <35 kg/m2 (BMI = weight (kg)/ [height (m)]2);
  5. Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below:

    1. Body temperature between 35.0-37.5 °C;
    2. Systolic blood pressure between 90-150 mm Hg;
    3. Diastolic blood pressure between 50-95 mm Hg;
    4. Pulse rate between 50-100 bpm.
  6. Willing and able to comply with study requirements;
  7. Subjects must be in good health as determined by past medical history, physical examination, electrocardiogram, clinical laboratory tests and urinalysis;

Exclusion Criteria:

  1. History of recent (within six months) drug or alcohol abuse;
  2. Any major surgery within three months of Day 1 or any minor surgery within one month;
  3. Donation or loss of 400 mL or more of blood within two months prior to the Baseline Visit;
  4. History or current evidence of cardiovascular, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction judged by the Investigator to be clinically significant;
  5. Any condition requiring the regular use of medication;
  6. History of intolerance and/or hypersensitivity to drugs including midazolam, rosiglitazone or other 'glitazones', melatonin or melatonin agonists, or anyone who has taken a melatonin preparation chronically within the past two months prior to Day 1;
  7. History of or current evidence of hypoglycemia judged by the Investigator to be clinically significant;
  8. History of liver disease and/or positive for one or more of the following serological results: HCV, HIV, HBsAg
  9. Treatment with any drug known to cause major organ system toxicity (e.g., chloramphenicol or tamoxifen) during the 60 day preceding Day 1;
  10. Elevated (> 2 times the upper limit of normal) liver function tests (i.e. aspartate aminotransferase (AST [SGOT]), alanine aminotransferase (ALT [SGPT]), and total bilirubin);
  11. Inability to be venipunctured and/or tolerate venous access;
  12. Subjects who have used tobacco products 3 months prior to dosing.
  13. Exposure to any investigational drug within 30 days or 5 half lives (whichever is longer) of baseline, including placebo;
  14. Participation in a previous BMS-214778/VEC-162 trial;
  15. Use of prescription or OTC medication, including herbal products (e.g., St. John's Wort) within 2 weeks of Day 1;
  16. Use of any food or beverage containing alcohol, grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family (e.g. kale, broccoli, watercress, collard greens, kohlrabi, brussel sprouts, mustard) and charbroiled meats within 1 week before Day 1 and during the actual duration of the study;
  17. Any other sound medical reason as determined by the clinical Investigator.
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01402076
VP-VEC-162-1110
No
Vanda Pharmaceuticals
Vanda Pharmaceuticals
Not Provided
Study Director: Vanda Pharmaceuticals Vanda Pharmaceuticals
Vanda Pharmaceuticals
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP